These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24300046)

  • 41. Treatment of Clostridium difficile infections.
    Soriano MM; Johnson S
    Infect Dis Clin North Am; 2015 Mar; 29(1):93-108. PubMed ID: 25573676
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101.
    Drugs R D; 2010; 10(1):37-45. PubMed ID: 20509714
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clarifications about add-on payments for fidaxomicin.
    Shah H; Tallman AM; Capurso S
    Am J Health Syst Pharm; 2013 Jun; 70(12):1015-6. PubMed ID: 23719875
    [No Abstract]   [Full Text] [Related]  

  • 44. Investigation of the MICs of fidaxomicin and other antibiotics against Hungarian Clostridium difficile isolates.
    Eitel Z; Terhes G; Sóki J; Nagy E; Urbán E
    Anaerobe; 2015 Feb; 31():47-9. PubMed ID: 25139122
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fidaxomicin: a new option for the treatment of Clostridium difficile infection.
    Johnson AP; Wilcox MH
    J Antimicrob Chemother; 2012 Dec; 67(12):2788-92. PubMed ID: 22865382
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
    Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S;
    Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful Therapy of Severe Pseudomembranous Clostridium difficile Colitis Using a Combination of Fecal Microbiota Therapy and Fidaxomicin.
    Konturek PC; Haziri D; Helfritzsch H; Hess T; Harsch IA
    Med Princ Pract; 2017; 26(2):182-184. PubMed ID: 27978522
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.
    Tart SB
    J Pharm Pract; 2013 Oct; 26(5):488-90. PubMed ID: 23940121
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clostridium difficile infections: what is new?].
    Miftode E; Leca D; Dorneanu O
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(3):656-61. PubMed ID: 22046768
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.
    Leeds JA
    Cold Spring Harb Perspect Med; 2016 Feb; 6(2):a025445. PubMed ID: 26834162
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin.
    Thabit AK; Alam MJ; Khaleduzzaman M; Garey KW; Nicolau DP
    Ann Clin Microbiol Antimicrob; 2016 Apr; 15():22. PubMed ID: 27071986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnosis and management of Clostridium difficile infection.
    Dupont HL
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1216-23; quiz e73. PubMed ID: 23542332
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New treatment options for infections with Clostridium difficile].
    van Nood E; Keller JJ; Kuijper EJ; Speelman P
    Ned Tijdschr Geneeskd; 2013; 157(48):A6580. PubMed ID: 24279951
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations.
    Goldenberg SD; Brown S; Edwards L; Gnanarajah D; Howard P; Jenkins D; Nayar D; Pasztor M; Oliver S; Planche T; Sandoe JA; Wade P; Whitney L
    Eur J Clin Microbiol Infect Dis; 2016 Feb; 35(2):251-9. PubMed ID: 26661400
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
    Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC
    J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antimicrobial activity of fidaxomicin against Clostridium difficile clinical isolates in Aichi area in Japan.
    Yamagishi Y; Nishiyama N; Koizumi Y; Matsukawa Y; Suematsu H; Hagihara M; Katsumata K; Mikamo H
    J Infect Chemother; 2017 Oct; 23(10):724-726. PubMed ID: 28527649
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Small Molecules Take A Big Step Against Clostridium difficile.
    Beilhartz GL; Tam J; Melnyk RA
    Trends Microbiol; 2015 Dec; 23(12):746-748. PubMed ID: 26547239
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clostridium difficile infection in older adults: a review and update on its management.
    Kee VR
    Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model.
    Chilton CH; Crowther GS; Todhunter SL; Ashwin H; Longshaw CM; Karas A; Wilcox MH
    J Antimicrob Chemother; 2015 Sep; 70(9):2598-607. PubMed ID: 26078392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.